GLENN CUNNINGHAM to Male
This is a "connection" page, showing publications GLENN CUNNINGHAM has written about Male.
Connection Strength
0.581
-
Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial. J Clin Endocrinol Metab. 2019 12 01; 104(12):6238-6246.
Score: 0.028
-
EFFICACY AND SAFETY OF A NEW TOPICAL TESTOSTERONE REPLACEMENT GEL THERAPY FOR THE TREATMENT OF MALE HYPOGONADISM. Endocr Pract. 2017 May; 23(5):557-565.
Score: 0.023
-
Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels. J Clin Endocrinol Metab. 2016 08; 101(8):3096-104.
Score: 0.022
-
Testosterone and metabolic syndrome. Asian J Androl. 2015 Mar-Apr; 17(2):192-6.
Score: 0.020
-
Association of sex hormones with sexual function, vitality, and physical function of symptomatic older men with low testosterone levels at baseline in the testosterone trials. J Clin Endocrinol Metab. 2015 Mar; 100(3):1146-55.
Score: 0.020
-
Effects of glycemia on immediate complications following CABG. Endocr Pract. 2013 Nov-Dec; 19(6):928-36.
Score: 0.018
-
Andropause or male menopause? Rationale for testosterone replacement therapy in older men with low testosterone levels. Endocr Pract. 2013 Sep-Oct; 19(5):847-52.
Score: 0.018
-
Diabetes and cardiovascular disease: what have we learned in 2012? Tex Heart Inst J. 2013; 40(3):290-2.
Score: 0.017
-
Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011 Jul; 34(7):1669-75.
Score: 0.015
-
Clinical review: Why is androgen replacement in males controversial? J Clin Endocrinol Metab. 2011 Jan; 96(1):38-52.
Score: 0.015
-
Testosterone replacement in men. Curr Opin Endocrinol Diabetes Obes. 2008 Aug; 15(4):364-70.
Score: 0.013
-
Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer. J Urol. 2007 Oct; 178(4 Pt 1):1521-7.
Score: 0.012
-
Hypogonadism in male patients with cancer. Cancer. 2006 Jun 15; 106(12):2583-91.
Score: 0.011
-
Testosterone replacement therapy for late-onset hypogonadism. Nat Clin Pract Urol. 2006 May; 3(5):260-7.
Score: 0.011
-
Comparison of the growth-promoting effects of testosterone and 7-alpha-methyl-19-nor-testosterone (MENT) on the prostate and levator ani muscle of LPB-tag transgenic mice. Prostate. 2006 Mar 01; 66(4):369-76.
Score: 0.011
-
Andropause: is androgen replacement therapy indicated for the aging male? Annu Rev Med. 2005; 56:117-37.
Score: 0.010
-
Gonadal and erectile dysfunction in diabetics. Med Clin North Am. 2004 Jul; 88(4):933-45, xi.
Score: 0.010
-
Androgen replacement in men with hypogonadism and erectile dysfunction. Endocrine. 2004 Mar-Apr; 23(2-3):143-8.
Score: 0.009
-
Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. J Clin Endocrinol Metab. 2024 Jan 18; 109(2):569-580.
Score: 0.009
-
Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open. 2023 12 01; 6(12):e2348692.
Score: 0.009
-
In vivo preservation of steroid specificity in CWR22 xenografts having a mutated androgen receptor. Prostate. 2003 Sep 15; 57(1):1-7.
Score: 0.009
-
Familial aggregation of prostate cancer in African-Americans and white Americans. Prostate. 2003 Sep 01; 56(4):256-62.
Score: 0.009
-
Hypogonadism and diabetes. Int J Impot Res. 2003 Aug; 15 Suppl 4:S14-20.
Score: 0.009
-
Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023 Jul 13; 389(2):107-117.
Score: 0.009
-
Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl. 2003 May-Jun; 24(3):299-311.
Score: 0.009
-
Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study. Am Heart J. 2022 03; 245:41-50.
Score: 0.008
-
Induction of apoptosis in BPH stromal cells by adenoviral-mediated overexpression of caspase-7. J Urol. 2000 Aug; 164(2):518-25.
Score: 0.007
-
Biomarkers and Noncalcified Coronary Artery Plaque Progression in Older Men Treated With Testosterone. J Clin Endocrinol Metab. 2020 07 01; 105(7).
Score: 0.007
-
Hormonal signaling in prostatic hyperplasia and neoplasia. J Clin Endocrinol Metab. 1999 Oct; 84(10):3463-8.
Score: 0.007
-
Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials. Lancet Diabetes Endocrinol. 2018 11; 6(11):879-890.
Score: 0.006
-
Validity and Clinically Meaningful Changes in the Psychosexual Daily Questionnaire and Derogatis Interview for Sexual Function Assessment: Results From the Testosterone Trials. J Sex Med. 2018 07; 15(7):997-1009.
Score: 0.006
-
Lessons From the Testosterone Trials. Endocr Rev. 2018 06 01; 39(3):369-386.
Score: 0.006
-
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018 05 01; 103(5):1715-1744.
Score: 0.006
-
The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials. J Clin Endocrinol Metab. 2018 02 01; 103(2):681-688.
Score: 0.006
-
Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME). J Sex Med. 2017 09; 14(9):1104-1115.
Score: 0.006
-
Androgen and sleep-related erections. J Psychosom Res. 1997 Jun; 42(6):541-6.
Score: 0.006
-
Lovastatin-induced apoptosis in prostate stromal cells. J Clin Endocrinol Metab. 1997 May; 82(5):1434-9.
Score: 0.006
-
Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial. JAMA Intern Med. 2017 04 01; 177(4):471-479.
Score: 0.006
-
Association of Testosterone Levels With Anemia in Older Men: A Controlled Clinical Trial. JAMA Intern Med. 2017 04 01; 177(4):480-490.
Score: 0.006
-
Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. JAMA. 2017 02 21; 317(7):708-716.
Score: 0.006
-
Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment. JAMA. 2017 02 21; 317(7):717-727.
Score: 0.006
-
Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME). Int J Clin Pract. 2016 Oct; 70(10):843-852.
Score: 0.006
-
Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men. BJU Int. 2017 Feb; 119(2):216-224.
Score: 0.006
-
Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016 Feb 18; 374(7):611-24.
Score: 0.005
-
Comparison of interactive voice response (IVR) with paper administration of instruments to assess functional status, sexual function, and quality of life in elderly men. Qual Life Res. 2016 Apr; 25(4):811-21.
Score: 0.005
-
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF TESTOSTERONE AND CARDIOVASCULAR RISK. Endocr Pract. 2015 Sep; 21(9):1066-73.
Score: 0.005
-
Inhibition of steroid 5 alpha-reductase with finasteride: sleep-related erections, potency, and libido in healthy men. J Clin Endocrinol Metab. 1995 Jun; 80(6):1934-40.
Score: 0.005
-
Recruitment and Screening for the Testosterone Trials. J Gerontol A Biol Sci Med Sci. 2015 Sep; 70(9):1105-11.
Score: 0.005
-
Anti-androgen effects of the aromatase inhibitor, atamestane. J Androl. 1995 Mar-Apr; 16(2):100-7.
Score: 0.005
-
The Testosterone Trials: Seven coordinated trials of testosterone treatment in elderly men. Clin Trials. 2014 06; 11(3):362-375.
Score: 0.005
-
Effects of 4-MAPC, a 5 alpha-reductase inhibitor, and cyproterone acetate on regrowth of the rat ventral prostate. Prostate. 1994 Apr; 24(4):212-20.
Score: 0.005
-
All men with vasculogenic erectile dysfunction require a cardiovascular workup. Am J Med. 2014 Mar; 127(3):174-82.
Score: 0.005
-
The assessment of vascular risk in men with erectile dysfunction: the role of the cardiologist and general physician. Int J Clin Pract. 2013 Nov; 67(11):1163-72.
Score: 0.004
-
Effects of finasteride on the rat ventral prostate. J Androl. 1993 Mar-Apr; 14(2):79-86.
Score: 0.004
-
Diagnosis and treatment of erectile dysfunction for reduction of cardiovascular risk. J Urol. 2013 Jun; 189(6):2031-8.
Score: 0.004
-
The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012 Aug; 87(8):766-78.
Score: 0.004
-
4-MAPC, a 5 alpha-reductase inhibitor, reduces rat ventral prostate weight, DNA, and prostatein concentrations. J Androl. 1991 Sep-Oct; 12(5):315-22.
Score: 0.004
-
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010 Jun; 95(6):2536-59.
Score: 0.004
-
Testosterone replacement therapy and sleep-related erections in hypogonadal men. J Clin Endocrinol Metab. 1990 Mar; 70(3):792-7.
Score: 0.004
-
Prostatein C3-mRNA: a sensitive marker of androgen-responsiveness in prostate explant cultures. Prostate. 1990; 17(1):41-55.
Score: 0.003
-
Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels. JAMA. 1989 May 05; 261(17):2525-30.
Score: 0.003
-
Acid phosphatase activity: a marker of androgen action in prostate explant cultures. Prostate. 1987; 10(1):69-77.
Score: 0.003
-
Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006 Jun; 91(6):1995-2010.
Score: 0.003
-
Age dependency of androgen and estrogen effects on incorporation of (3H)-thymidine by rat prostates in organ culture. Prostate. 1986; 8(4):349-62.
Score: 0.003
-
New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab. 2004 Aug; 89(8):3821-9.
Score: 0.002
-
Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004 May; 89(5):2085-98.
Score: 0.002
-
Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004 May; 89(5):2179-84.
Score: 0.002
-
Androgen antagonists in androgen target tissues. Pharmacol Ther. 1984; 24(3):367-400.
Score: 0.002
-
Characterization of steroid binding specificity of the androgen receptor in human foreskin fibroblasts. Steroids. 1983 May; 41(5):617-26.
Score: 0.002
-
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem--2003 update. Endocr Pract. 2003 Jan-Feb; 9(1):77-95.
Score: 0.002
-
Steroid structural requirements for high affinity binding to human sex steroid binding protein (SBP). Steroids. 1981 Sep; 38(3):243-62.
Score: 0.002
-
Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol (Oxf). 2001 Jun; 54(6):739-50.
Score: 0.002
-
Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000 Dec; 85(12):4500-10.
Score: 0.002
-
Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000 Aug; 85(8):2839-53.
Score: 0.002
-
The potential for an androgen male contraceptive. J Clin Endocrinol Metab. 1979 Oct; 49(4):520-6.
Score: 0.002
-
Persistence of complete spermatogenesis in the presence of low intratesticular concentrations of testosterone. Endocrinology. 1979 Jul; 105(1):177-86.
Score: 0.002
-
Differences in steroid specificity for rat androgen binding protein and the cytoplasmic receptor. Steroids. 1979 Mar; 33(3):261-76.
Score: 0.002
-
Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Res. 1999 Jan 15; 59(2):382-90.
Score: 0.002
-
Serum FSH, LH, and testosterone in 60Co gamma-irradiated male rats. Radiat Res. 1978 Nov; 76(2):331-8.
Score: 0.002
-
Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res. 1998 Jan 01; 58(1):76-83.
Score: 0.002
-
Mechanisms for the testicular hypertrophy which follows hemicastration. Endocrinology. 1978 Jan; 102(1):16-23.
Score: 0.002
-
An FSH and prolactin-secreting pituitary tumor: pituitary dynamics and testicular histology. J Clin Endocrinol Metab. 1977 Feb; 44(2):248-53.
Score: 0.001
-
Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. Diabetes Care. 1995 Jun; 18(6):843-51.
Score: 0.001
-
Abnormal growth hormone dynamics in chronic liver disease do not depend on severe parenchymal disease. Metabolism. 1990 Apr; 39(4):349-56.
Score: 0.001
-
Monoclonal antibodies against the androgen receptor: recognition of human and other mammalian androgen receptors. Endocrinology. 1988 Jul; 123(1):601-10.
Score: 0.001
-
Plasma growth hormone during sleep in young and aged men. J Gerontol. 1983 Sep; 38(5):519-24.
Score: 0.001
-
Isolated deficiency of adrenocorticotropin (ACTH) and lipotropins (LPHs). J Clin Endocrinol Metab. 1978 Jul; 47(1):84-90.
Score: 0.000
-
5alpha-Dihydrotestosterone binding to androgen binding protein. Effects of testosterone and other compounds in vivo and in vitro on the number of binding sites measured. J Biol Chem. 1978 Jan 10; 253(1):166-9.
Score: 0.000